Patents by Inventor Padmanabh P. Bhatt

Padmanabh P. Bhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160279136
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. VIEIRA, Austin B. HUANG, Padmanabh P. BHATT
  • Publication number: 20160263042
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Application
    Filed: May 24, 2016
    Publication date: September 15, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • Publication number: 20160256465
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Application
    Filed: May 18, 2016
    Publication date: September 8, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. VIEIRA, Austin B. HUANG, Padmanabh P. BHATT
  • Patent number: 9434703
    Abstract: Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 6, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Padmanabh P. Bhatt, David Dain, Jean-Philippe Taquet, Aleksandr Pechenov, Alexei Tchesnokov, Reynold Mariaux
  • Patent number: 9403783
    Abstract: Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: August 2, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Padmanabh P. Bhatt, David Dain, Jean-Philippe Taquet, Aleksandr Pechenov, Alexei Tchesnokov, Reynold Mariaux
  • Patent number: 9393203
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: July 19, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • Patent number: 9370525
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: June 21, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Patent number: 9358204
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 7, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
  • Patent number: 9351975
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: May 31, 2016
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Publication number: 20160030355
    Abstract: An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.
    Type: Application
    Filed: October 13, 2015
    Publication date: February 4, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P Bhatt
  • Publication number: 20160022596
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Application
    Filed: February 24, 2015
    Publication date: January 28, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Hua WANG, Padmanabh P. BHATT, Michael L. VIEIRA
  • Publication number: 20160008285
    Abstract: Formulations of mazindol having superior stability and methods of administering same are provided. The formulations may be immediate, enhanced, or otherwise delayed release formulations of mazindol.
    Type: Application
    Filed: September 1, 2015
    Publication date: January 14, 2016
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Argaw Kidane, Padmanabh P. Bhatt
  • Publication number: 20150359800
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility-and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: August 26, 2015
    Publication date: December 17, 2015
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Publication number: 20150359748
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: July 23, 2015
    Publication date: December 17, 2015
    Applicant: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Patent number: 9119791
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: September 1, 2015
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Patent number: 9119792
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: September 1, 2015
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Publication number: 20150126735
    Abstract: Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.
    Type: Application
    Filed: December 19, 2014
    Publication date: May 7, 2015
    Applicant: Supernus Pharmaceuticals Inc.
    Inventors: Likan Liang, Padmanabh P. Bhatt, David Dain, Jean-Philippe Taquet, Aleksandr Pechenov, Alexei Tchesnokov, Reynold Mariaux
  • Publication number: 20150099739
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: July 29, 2014
    Publication date: April 9, 2015
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Publication number: 20150094301
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: July 29, 2014
    Publication date: April 2, 2015
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Patent number: 8992989
    Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: March 31, 2015
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Likan Liang, Hua Wang, Padmanabh P. Bhatt, Michael L. Vieira